ChiCTR-OPC-14005353
正在进行
/
/
/
2014-09-11
/
/
Patients with post-traumatic chronic wrist pain, with imaging and previous arthroscopic evidence of wrist carpal bone chondral defects who opt for active treatment
臨床試驗研究 –「自體間質幹細胞治療腕關節軟骨缺損」
臨床試驗研究 –「自體間質幹細胞治療腕關節軟骨缺損」
自體間質幹細胞治療腕關節軟骨缺損
单臂
治疗新技术
N/A
/
The Chinese University of Hong Kong
/
20
/
2014-10-01
1990-01-01
/
1. Wrist pain of mechanical origin(post-traumatic); 2. The pain cannot be relieved by treating other underlying defects other than carpal affections; 3. Patients with imaging and previous arthroscopic evidence of wrist carpal bone chondral defects; 4. Absence of any local or general infection; 5. Hematologic and biochemical analyses with no significant alterations that contraindicate intervention; 6. Patient who is able to understand the nature the study and provide informed written consent.；
请登录查看1. Age older than 75 or younger than 18 years old or legally dependent; 2. Patients with past history of hematologic disorders; 3. Signs of infection or positive serology for HIV, HBV, HCV, or syphilis; 4. Congenital or acquired diseases leading to significant wrist deformities that may interfere with cell application or interpretation of results; 5. Pregnancy or breast, feeding, Neoplasia, Immunosuppression, Participation in another clinical trial or treatment with another investigational product within 30 days before inclusion in the study; 6. Patients with alcoholism/drug abuse; 7. Other medical conditions that may discourage participation in the study.；
请登录查看Dr. WL Tse
/
Dr. WL Tse的其他临床试验
Department of Orthopaedics and Traumatoloy, Prince of Wales Hospital, Shatin, Hong Kong的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 60
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04